← Patent-cliff monitor small molecule ETCAMAH CAMIZESTRANT
Loss of exclusivity October 2041 latest FDA-listed patent expiry
Company ASTRAZENECA PHARMACEUTICALS LP
Drug detail Brand name ETCAMAH Active ingredient CAMIZESTRANT Strength 75MG Dosage form TABLET Route ORAL Modality Small molecule FDA approval September 2026 Marketing status RX
Listed patents Patent Expires Type 12453729 October 2041 product 12364689 September 2041 use U-4606 12077530 October 2037 use U-4607 10961241 October 2037 use U-4607 10590130 October 2037 substance, product 10131663 October 2037 substance, product
Regulatory exclusivity Code Expires NCE September 2031
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.